Martin Shkreli, former chief executive officer of Turing Pharmaceuticals AG, exits court in New York, US, on Wednesday, Oct. 4, 2023.
Yuki Iwamura | Bloomberg | Getty Images
A federal appeals court on Tuesday upheld a lifetime ban on “Pharma bro” Martin Shkreli from working in the pharmaceuticals industry.
The ruling by a three-judge panel on the 2nd U.S. Circuit Court of Appeals came two years after a federal judge slapped the ban on Shkreli for the monopolistic behavior of his then-drug company in selling the medication Daraprim.
The Federal Trade Commission and seven states, among them New York and California, had sued Shkreli in the case.
Shkreli previously served a prison term for federal securities fraud and other financial crimes not related to his controversial price hike of Daraprim in 2015.
This is breaking news. Please check back for updates.
